{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:37Z","timestamp":1707524617334},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,13]]},"DOI":"10.7759\/cureus.24098","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T09:59:06Z","timestamp":1649843946000},"source":"Crossref","is-referenced-by-count":0,"title":["Healthcare Disparities in the Management of Indolent Mycosis Fungoides"],"prefix":"10.7759","author":[{"given":"M\u0103d\u0103lina Laura","family":"Banciu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Codruta","family":"Dobrica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Soare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Malciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad Mihai","family":"Voiculescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Mycosis Fungoides","author":"Vaidya T","year":"202130137856","unstructured":"Vaidya T, Badri T. Mycosis Fungoides. StatPearls Publishing, Treasure Island, FL; 202130137856."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20187106","article-title":"Clinical and epidemiological profile of patients with early stage mycosis fungoides","volume":"93","author":"Amorim GM","year":"2018","unstructured":"Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018, 93:546-52. 10.1590\/abd1806-4841.20187106","journal-title":"An Bras Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and S\u00e9zary Syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garc\u00eda-D\u00edaz N","year":"2021","unstructured":"Garc\u00eda-D\u00edaz N, Piris M\u00c1, Ortiz-Romero PL, Vaqu\u00e9 JP. Mycosis fungoides and S\u00e9zary Syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers. 2021, 13:1-24. 10.3390\/cancers13081931","journal-title":"Cancers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim YH","year":"1996","unstructured":"Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996, 132:1309-13. 10.1001\/archderm.1996.03890350051009","journal-title":"Arch Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1590\/s0365-05962012000600001","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical, histopathological and immunohistochemical review and update","volume":"87","author":"Yamashita T","year":"2012","unstructured":"Yamashita T, Abbade LP, Marques ME, Marques SA. Mycosis fungoides and S\u00e9zary syndrome: clinical, histopathological and immunohistochemical review and update. An Bras Dermatol. 2012, 87:817-28. 10.1590\/s0365-05962012000600001","journal-title":"An Bras Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze R","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019, 133:1703-14. 10.1182\/blood-2018-11-881268","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN Guidelines Insights: primary cutaneous lymphomas, Version 2.2020","volume":"18","author":"Mehta-Shah N","year":"2020","unstructured":"Mehta-Shah N, Horwitz SM, Ansell S, et al.. NCCN Guidelines Insights: primary cutaneous lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020, 18:522-36. 10.6004\/jnccn.2020.0022","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12701","article-title":"DNA from human polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in cutaneous T-cell lymphomas","volume":"38","author":"Bergallo M","year":"2018","unstructured":"Bergallo M, Dapr\u00e0 V, Fava P, et al.. DNA from human polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in cutaneous T-cell lymphomas. Anticancer Res. 2018, 38:4111-4. 10.21873\/anticanres.12701","journal-title":"Anticancer Res"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1097\/00000372-197901010-00002","article-title":"The patch stage of mycosis fungoides. Criteria for histologic diagnosis","volume":"1","author":"Sanchez JL","year":"1979","unstructured":"Sanchez JL, Ackerman AB. The patch stage of mycosis fungoides. Criteria for histologic diagnosis. Am J Dermatopathol. 1979, 1:5-26.","journal-title":"Am J Dermatopathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.08.004","article-title":"Mycosis fungoides","volume":"65","author":"Zinzani PL","year":"2008","unstructured":"Zinzani PL, Ferreri AJ, Cerroni L. Mycosis fungoides. Crit Rev Oncol Hematol. 2008, 65:172-82. 10.1016\/j.critrevonc.2007.08.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino P","year":"2012","unstructured":"Quaglino P, Pimpinelli N, Berti E, et al.. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer. 2012, 118:5830-9. 10.1002\/cncr.27627","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim HS","year":"1999","unstructured":"Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999, 40:418-25. 10.1016\/S0190-9622(99)70491-3","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur R","year":"2012","unstructured":"Talpur R, Singh L, Daulat S, et al.. Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin Cancer Res. 2012, 18:5051-60. 10.1158\/1078-0432.CCR-12-0604","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.100491","article-title":"Prognostic factors of patients with mycosis fungoides","volume":"37","author":"Bahal\u0131 AG","year":"2020","unstructured":"Bahal\u0131 AG, Su O, Cengiz FP, Emiro\u011flu N, Ozkaya DB, Onsun N. Prognostic factors of patients with mycosis fungoides. Postepy Dermatol Alergol. 2020, 37:796-9. 10.5114\/ada.2020.100491","journal-title":"Postepy Dermatol Alergol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9554.1000342","article-title":"Prognostic significance of serum lactate dehydrogenase in Saudi Patients with mycosis fungoides: a retrospective study of 47 patients","volume":"7","author":"Saif FA","year":"2016","unstructured":"Saif FA. Prognostic significance of serum lactate dehydrogenase in Saudi Patients with mycosis fungoides: a retrospective study of 47 patients. J Clin Exp Dermatol Res. 2016, 7:1-4. 10.4172\/2155-9554.1000342","journal-title":"J Clin Exp Dermatol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1820","article-title":"Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy","volume":"7","author":"Feng Y","year":"2018","unstructured":"Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018, 7:6124-36. 10.1002\/cam4.1820","journal-title":"Cancer Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2013.07.009","article-title":"The current management of mycosis fungoides and S\u00e9zary syndrome and the role of radiotherapy: Principles and indications","volume":"19","author":"Mazzeo E","year":"2014","unstructured":"Mazzeo E, Rubino L, Buglione M, et al.. The current management of mycosis fungoides and S\u00e9zary syndrome and the role of radiotherapy: Principles and indications. Rep Pract Oncol Radiother. 2014, 19:77-91. 10.1016\/j.rpor.2013.07.009","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek G","year":"1999","unstructured":"Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999, 86:1368-76.","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes CF","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C, et al.. Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood. 2015, 125:71-81. 10.1182\/blood-2014-07-588236","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"114","author":"Prince HM","year":"2009","unstructured":"Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and S\u00e9zary syndrome. Blood. 2009, 114:4337-53. 10.1182\/blood-2009-07-202895","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/92647-healthcare-disparities-in-the-management-of-indolent-mycosis-fungoides","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:42Z","timestamp":1707507462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/92647-healthcare-disparities-in-the-management-of-indolent-mycosis-fungoides"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.24098","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}